Navigation Links
Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension
Date:5/31/2012

MONMOUTH JUNCTION, N.J., May 31, 2012 /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved the first-ever generic to Delsym®, an extended-release oral liquid suspension containing dextromethorphan polistirex.

Delsym was approved in 1982 and there has never been any generic alternative approved until now. Tris has pioneered the delivery of drugs in taste-neutral, extended release dosage forms such as liquids, ODT/chewable tablets, and strips that are otherwise associated with immediate release. Tris' versatile, patented technology avoids the use of toxic organic solvents by employing aqueous-based coating.

"This is the third extended-release liquid product approved by the FDA based on our patented technology, and speaks to Tris' capabilities to develop and commercialize difficult products," said Ketan Mehta, President & CEO of Tris Pharma.  "Leveraging our technology, Tris has built a robust and deep pipeline of unique products that will address many of today's unmet needs."

Perrigo is Tris' exclusive partner in distributing this product as a store-brand alternative to Delsym, and has announced that it will be shipping the product for the coming cough/cold/flu season.  Annual sales across the entire Delsym brand are estimated at more than $100 million.

Delsym is a registered trademark of Reckitt Benckiser, which is not associated with Tris Pharma or Tris' generic product.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit www.trispharma.com.


'/>"/>
SOURCE Tris Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
2. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
3. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
4. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
5. Clean Room Environmental Best Practices for Medical Device & Pharmaceutical Manufacturers are Focus of Boston Seminar on June 6
6. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
7. Isis Pharmaceuticals to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
9. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
10. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
11. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to ... Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final ... and levels of the game, Connor Sports has committed to a significantly increased focus ...
(Date:5/26/2016)... Pompano Beach, Florida (PRWEB) , ... May 26, 2016 , ... ... Green House® Project offering a new model of care for living and ... on three core values: Meaningful Life in a Real Home provided by Empowered Staff. ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 ... 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world ... Cancer Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration ...
(Date:5/26/2016)... ... 26, 2016 , ... Catalent Pharma Solutions, the leading global ... and global clinical supply services, today announced two key appointments and the opening ... and strategic growth plans in the Asia Pacific region. , Howard Kim has ...
Breaking Medicine News(10 mins):